CA-ANDERSEN-GLOBAL
29.6.2022 13:11:10 CEST | Business Wire | Pressemeddelelse
Andersen Global etablerer skattemæssige og juridiske kompetencer i New Zealand gennem samarbejdsaftaler med to virksomheder beliggende i Auckland – advokatfirmaet Turner Hopkins og skatte- og rådgivningsfirmaet Bellingham Wallace. Virksomhederne opretholder solide forbindelser i regionen og vil spille en central rolle i at drive forretning og levere integrerede, globale løsninger for at skabe langsigtet værdi for kunderne.
Turner Hopkins blev grundlagt i 1923 og har i næsten 100 år leveret fuldservice-kompetencer inden for ejendomsret, selskabs- og erhvervsret, procesførelse, finans, ansættelsesret, familieret, private kunder, ejendoms- og immigrationsret. Turner Hopkins’ tværfaglige team af fagfolk har stor erfaring med at arbejde på tværs af en række brancher og tage sig af kundernes behov med omfattende, skræddersyede løsninger.
”Vi er stolte over vores kundefokuserede tilgang og vores forpligtelse til at sikre, at vi fastholder den højeste kaliber af advokater og fagfolk, hvilket har gjort det muligt for os at opretholde en konkurrencefordel i Auckland-regionen i næsten et århundrede,” siger ledende partner Michael Robinson. ”Samarbejdet med Andersen Global gør os i stand til fortsat at arbejde problemfrit med kunder og levere kvalitetsløsninger til kunder med stigende globale behov”.
Bellingham Wallace blev etableret i 2012 og grundlagt af to ledende partnere Matt Bellingham og Aaron Wallace, for at arbejde tæt sammen med kunder lige fra små til store privatejede virksomheder. Virksomheden tilbyder en række fuldservice-kompetencer inden for rådgivning, ledelse, skat, strategi, due diligence og værdiansættelse for at drive vækst og styre risici for kundernes virksomheder.
”Vores virksomhed har oplevet enestående vækst i løbet af de seneste par år, alt imens vi fortsætter med at prioritere alle vores kunders behov og udvide vores eksisterende kapaciteter på markedet,” siger medgrundlægger og ledende medpartner Matt Bellingham. ”Samarbejdet med Andersen Global viser vores forpligtelse til ekspertise og styrker vores kundefokuserede tilgang, da de yderligere globale ressourcer vil styrke vores evne til at imødekomme kundernes skiftende behov,” tilføjer Aaron Wallace.
Andersen Globals bestyrelsesformand og CEO Mark Vorsatz siger: ”Turner Hopkins og Bellingham Wallace vil være store aktiver i vores bestræbelse på at imødekomme vores voksende behov i regionen. Disse virksomheder deler vores organisations engagement i ledelse og udviser de højeste professionelle standarder, og vi forudser et synergistisk samarbejde mellem vores fagfolk. Det er vigtigt for os at samarbejde med disse virksomheder, mens vi fortsat giver klassens bedste løsninger til vores kunder over hele kloden og styrker vores tilstedeværelse i Asien og Stillehavsområdet.”
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsvirksomheder, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013, og Andersen Global har nu over 11.000 fagfolk på verdensplan og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220628005502/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
